Navigation Links
Amicus Therapeutics Presents Preclinical Data from Studies of,Plicera for Gaucher Disease

Studies Show Increased Enzyme Levels in Two Most Common Mutations

CRANBURY, N.J., March 20, 2007 /PRNewswire/ -- Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of a range of human genetic diseases, announced today that it will present the results of preclinical studies of Plicera(TM) (isofagomine tartrate, AT2101) for Gaucher disease at the of Medical Genetics (ACMG) annual meeting March 21-25 in Nashville, TN. The data demonstrate the ability of Plicera to increase levels of the target enzyme in cells derived from a patient with the N370S mutation and in mice that express the L444P mutation. The N370S and the L444P are the two most common mutations associated with Gaucher disease. Additional data from both studies will also be presented.

Plicera is designed to selectively bind to and stabilize GCase, the enzyme deficient in Gaucher disease. This deficiency leads to lysosomal accumulation of glucocerebroside inside certain cells, which is believed to cause the various symptoms of Gaucher disease. Plicera facilitates proper trafficking of the enzyme to the lysosomes, the compartments in the cell where it is needed to break down glucocerebroside.

The following is a summary of the preclinical Plicera data being presented at ACMG.

    - In vitro exposure to Plicera increased transport of GCase to the

      lysosomes in cells derived from a patient with the N370S mutation.

      Once in the lysosome, the enzyme was stable and active for more than 3

      days after Plicera was removed. The N370S is the most common mutation

      associated with Gaucher disease in the Western world.  These studies

      were published in the September 12, 2006 issue of the Proceedings of the

      National Academy of Sciences (PNAS).


    - Oral administration of Plicera resulted in a dose-dependent increase of
'"/>




Page: 1 2 3

Related medicine technology :

1. Amicus Therapeutics Presents Positive Results From Phase 1 Clinical Studies of Plicera for Gaucher Disease
2. Amicus Therapeutics Presents Data From Preclinical and Phase 1 Studies of Amigal for Fabry Disease
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
5. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
6. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
7. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
8. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
(Date:10/20/2014)... DIEGO , Oct. 20, 2014  ResMed ... availability of the ResMed Data Exchange program, a ... home medical equipment (HME) and other health care ... timely, secure access to critical patient information. It ... ResMed,s AirView™ and U-Sleep™ patient management platforms with ...
(Date:10/20/2014)... 20, 2014  AnaptysBio, Inc., a leader in ... announced the appointment of Marco Londei , ... lead the preclinical and clinical development of AnaptysBio,s ... pleased to welcome Dr. Londei to AnaptysBio,s executive ... and Chief Executive Officer of AnaptysBio. "Dr. Londei,s ...
(Date:10/20/2014)... Pharmaceutic Labs announces the opening of its ... NY for admixing, compounding, drug shortages and ... the FDA standards for safety and quality, using 21 ... The 10,000 square foot outsourcing facility was ... and quality control. The company will produce sterile and ...
Breaking Medicine Technology:ResMed Launches ResMed Data Exchange 2AnaptysBio Appoints Dr. Marco Londei to Newly Created Chief Development Officer Position Clinical Immunologist to Lead AnaptysBio's Pipeline Advancement 2
... Reduced By an Average of More Than ... N.C., April 02, 2007 /PRNewswire/ --,Adding the ... 24-Hour(TM) Extended-Release Tablets to,Parkinson's patients' existing levodopa ... to continue,their daily activities for a longer ...
... MUNICH, Germany, April 03, 2007 /PRNewswire/ -- ... showing the,improved potency of oritavancin to stop ... common wetting agent (polysorbate 80) and one,study ... in a mouse model of pneumonia. Oritavancin, ...
Cached Medicine Technology:Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 2Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 3Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 4Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 5Targanta Reports Improved Ability of Oritavancin to Stop Bacteria,Growth In Vitro Compared With Other Glycopeptide Antibiotics 2Targanta Reports Improved Ability of Oritavancin to Stop Bacteria,Growth In Vitro Compared With Other Glycopeptide Antibiotics 3Targanta Reports Improved Ability of Oritavancin to Stop Bacteria,Growth In Vitro Compared With Other Glycopeptide Antibiotics 4Targanta Reports Improved Ability of Oritavancin to Stop Bacteria,Growth In Vitro Compared With Other Glycopeptide Antibiotics 5Targanta Reports Improved Ability of Oritavancin to Stop Bacteria,Growth In Vitro Compared With Other Glycopeptide Antibiotics 6
(Date:10/20/2014)... Diego, CA (PRWEB) October 20, 2014 AttorneyOne.com, ... all the latest information from the FDA on Sit ... on October 10 not to purchase or use Sit and ... Sit and Slim II is promoted as weight loss product ... Sibutramine, removed from the market in 2010 for safety reasons, ...
(Date:10/20/2014)... Succeed is proud to announce that they ... in the Every Body Walk! campaign by Kaiser ... that encourages workers to be more active outside of the ... concluded at the end of September, was a friendly competition ... areas. Participating companies gave their staff pedometers and each ...
(Date:10/20/2014)... Viejo, California (PRWEB) October 20, 2014 Final ... announced the release of the Citrus theme for FCPX ... I would use to describe the Citrus theme” Says Christina ... so easy to look so professional.” , Citrus comes with ... Included with the template are: four transitions for added style, ...
(Date:10/20/2014)... Punzoné , the first line of ultra-premium ... lot to celebrate this month. October marks Italian Heritage Month ... contributions of Americans of Italian heritage and Italians in America. ... shares its favorite Italian cocktails and encourages everyone to enjoy ... if it is only in a glass. , Punzoné ...
(Date:10/19/2014)... October 20, 2014 Hastings and Hastings, ... years of service throughout the greater Phoenix area and ... representation with regard to catastrophic automobile accidents. Statistics have ... country and throughout Arizona. As such, Hastings and Hastings ... legal representation for those who have been injured through ...
Breaking Medicine News(10 mins):Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Today Pixel Film Studios Announced the Release of the Citrus theme for Final Cut Pro X 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 4Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 3
... treatment vs. watchful waiting , MONDAY, July 27 (HealthDay ... who have prostate cancer surgery but leaves unanswered the complicated ... treatment or just watchful waiting. , The study of almost ... removal of a cancerous prostate gland -- between 1987 and ...
... , , WASHINGTON, ... the National Press Club. National Press Club events are open to ... and Newsmakers. Events listed are subject to last-minute changes. Space may ... time and avoid waiting in line, tickets can be paid for ...
... (LRF) is pleased to announce that the 2009 Millennium ... has been awarded to Kai Fu, MD, PhD, Associate ... , Lymphoma, the most common type of ... and non-Hodgkin lymphoma (NHL). According to a 2008 ...
... in never-smokers is poorly understood, but a study led by ... at the National Cancer Institute has identified a molecule believed ... , The findings, published online recently in the Proceedings ... improved therapy for lung cancer in both never-smokers and smokers, ...
... , , PITTSBURGH, July 27 Childhood ... young adults and can lead to premature death in adulthood ... hypertension. In addition to its significant human toll, childhood obesity ... annually. , , To address the continued ...
... A ... the American Society of Andrology,s annual meeting. Study results showed marked improvement in sperm ... the ejaculate. , ... Bellingham, WA (PRWEB) July 23, 2009 -- A clinical study for the male fertility ...
Cached Medicine News:Health News:Men Who Have Prostate Cancer Surgery Do Well 2Health News:Men Who Have Prostate Cancer Surgery Do Well 3Health News:Millennium Pharmaceuticals Inc./Lymphoma Research Foundation funds lymphoma research 2Health News:Molecule plays early role in nonsmoking lung cancer 2Health News:Highmark Provides Pediatricians With Resources to Combat Childhood Obesity 2Health News:Highmark Provides Pediatricians With Resources to Combat Childhood Obesity 3Health News:Male Fertility Supplement Improves Sperm Quality & Motility in Clinical Study 2Health News:Male Fertility Supplement Improves Sperm Quality & Motility in Clinical Study 3Health News:Male Fertility Supplement Improves Sperm Quality & Motility in Clinical Study 4
Sharp tipped straight scissors. For cutting in the iris plane or cutting peripheral membranes. May also be useful in ROP cases....
Microscissors : Horizontal Scissors...
Low profile, sharp-tipped scissors with a vertical cutting action. Excellent for peeling and cutting fine epiretinal membranes....
... with a curvature of 12 ... of the retina. Instrument shaft ... For cutting membranes adherent to ... for cutting in small folds ...
Medicine Products: